WARF: P06288US

Vitamin D Compounds for the Treatment of Ocular Hypertension


Hector DeLuca, Galina Kutuzova, Paul Kaufman, B'Ann Gabelt

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method of using a vitamin D analog to treat ocular hypertension.
OVERVIEWGlaucoma, the second leading cause of blindness, is an eye disease that results in optic nerve damage and loss of vision.  Glaucoma usually is associated with elevated intraocular pressure (IOP).  In individuals with ocular hypertension (OHT), IOP is elevated without optic nerve damage or visual field loss.  Such individuals are at greater risk for developing glaucoma.
THE INVENTIONUW–Madison researchers have developed a method of treating OHT by administering a vitamin D analog.  The vitamin D compound can be applied topically to one or both of an individual’s eyes to reduce IOP.
  • Treating OHT, thereby reducing the risk of developing glaucoma
  • Provides a safe and effective treatment for OHT
  • Can be administered in several forms, including eye drops, solutions and ointments
  • May be combined with antimicrobial compounds
For More Information About the Inventors
Contact Information
For current licensing status, please contact Rafael Diaz at or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.